EPHA2 and esophageal cancer: For instance, Cell Cycle Inhibitors such as Etoposide have shown efficacy in cancers with TP53 mutations.[54] Additionally, EPHA2-targeted therapies, which include small-molecule inhibitors and monoclonal antibodies, are currently being explored in clinical trials for other cancers, such as lung and esophageal cancer.